201 related articles for article (PubMed ID: 33686514)
21. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.
Balupuri A; Balasubramanian PK; Cho SJ
Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602
[TBL] [Abstract][Full Text] [Related]
22. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
23. Estimation of the ligand-binding free energy of checkpoint kinase 1 via non-equilibrium MD simulations.
Mai NT; Lan NT; Vu TY; Duong PTM; Tung NT; Phung HTT
J Mol Graph Model; 2020 Nov; 100():107648. PubMed ID: 32653524
[TBL] [Abstract][Full Text] [Related]
24. Selected arylsulphonyl pyrazole derivatives as potential Chk1 kinase ligands-computational investigations.
Czaja K; Kujawski J; Kamel K; Bernard MK
J Mol Model; 2020 May; 26(6):144. PubMed ID: 32424505
[TBL] [Abstract][Full Text] [Related]
25. Computational investigation of potent inhibitors against SARS-CoV-2 2'-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, molecular docking, molecular dynamics simulations and binding free energy calculations.
Shi L; Wen Z; Song Y; Wang J; Yu D
J Mol Graph Model; 2022 Dec; 117():108306. PubMed ID: 36063745
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening.
Yilmaz OG; Olmez EO; Ulgen KO
Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487
[TBL] [Abstract][Full Text] [Related]
27. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
[TBL] [Abstract][Full Text] [Related]
28. Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.
Parate S; Kumar V; Hong JC; Lee KW
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917039
[TBL] [Abstract][Full Text] [Related]
29. Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants.
Singh R; Bhardwaj VK; Sharma J; Das P; Purohit R
Genomics; 2021 Jan; 113(1 Pt 2):707-715. PubMed ID: 33065246
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors.
Hammad S; Bouaziz-Terrachet S; Meghnem R; Meziane D
J Mol Model; 2020 May; 26(6):160. PubMed ID: 32472293
[TBL] [Abstract][Full Text] [Related]
31. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
32. Identification of Pak1 inhibitors using water thermodynamic analysis.
Biswal J; Jayaprakash P; Suresh Kumar R; Venkatraman G; Poopandi S; Rangasamy R; Jeyaraman J
J Biomol Struct Dyn; 2020 Jan; 38(1):13-31. PubMed ID: 30661460
[TBL] [Abstract][Full Text] [Related]
33. In Silico Exploration of 1,7-Diazacarbazole Analogs as Checkpoint Kinase 1 Inhibitors by Using 3D QSAR, Molecular Docking Study, and Molecular Dynamics Simulations.
Gao X; Han L; Ren Y
Molecules; 2016 May; 21(5):. PubMed ID: 27164065
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.
Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R
Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
[TBL] [Abstract][Full Text] [Related]
36. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
[TBL] [Abstract][Full Text] [Related]
37. Computational design of new protein kinase D 1 (PKD1) inhibitors: homology-based active site prediction, energy-optimized pharmacophore, docking and database screening.
Nalini ; Chadha N; Bahia MS; Kaur M; Bahadur R; Silakari O
Mol Divers; 2018 Feb; 22(1):47-56. PubMed ID: 29058231
[TBL] [Abstract][Full Text] [Related]
38. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
Elseginy SA
J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
[TBL] [Abstract][Full Text] [Related]
40. Virtual Screening Using Pharmacophore Models Retrieved from Molecular Dynamic Simulations.
Polishchuk P; Kutlushina A; Bashirova D; Mokshyna O; Madzhidov T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
